EBS Total Utang marang Modal Emergent Corp

EBS (Emergent Corp) - tandha merek perusahaan

Emergent BioSolutions (EBS) is scaling its operations through US defense contracts, ensuring high capacity utilization for antidote production. Effective supply chain diversification and strict adherence to temperature controls guarantee stable sales. However, reliance on the government budget and production costs create risks. This chart's price trend shows that the total debt-to-equity ratio stands at 1.81, limiting the company's maneuverability.

EBS Rasio Kabeh Utang marang Dana Pribadi Emergent BioSolutions Inc. (04.07.2022 - 28.10.2026)

Rincian analitis perusahaan Emergent BioSolutions

- rega lan prakiraan konsensus rega:
Rega saham Emergent BioSolutions Inc.|EBS - Konsensus nilai wajar
- data kapitalisasi pasar:
Kapitalisasi pasar Emergent BioSolutions|EBS - Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Emergent BioSolutions|EBS - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku emergentbiosolutions.com|EBS - Gunggung Aset Perusahaan
- data utang lan likuiditas:
Total Utang marang Modal Emergent BioSolutions|EBS - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Emergent BioSolutions|EBS - Kewajiban utang agregat|Utang marang nilai buku Emergent BioSolutions
Analisis komprehensif perusahaan:EBS, Emergent BioSolutions Inc.
Produk dadi emergentbiosolutions.com

Professional capital evaluates the profile of Emergent BioSolutions (EBS) through the lens of its debt load. This total debt-to-equity ratio measures the proportion of borrowed funds within the business's financing structure. A decrease in this metric minimizes credit risks while simultaneously limiting expansion rates. For a company with government vaccine contracts, such stability confirms the resilience of its "economic moat." A low level of leverage guarantees the high financial reliability of the asset.

Pesaing utama

GILD - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi Cidara|Total Utang marang Modal NVAX|Total Utang marang Modal CVAC (CureVac Pharma)|Utang marang Ekuitas Valneva SE|vir.bio - Rasio Kabeh Utang marang Dana Pribadi|SIGA: Utang marang Ekuitas|AVIR - Rasio Total Utang marang Ekuitas|IVVD: Total Utang marang Modal|Total Utang marang Modal Enanta Pharmaceuticals, Inc|INO - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi hillevax.com (HLVX)|Rasio Total Utang marang Ekuitas Kalaris Therapeutics (KLRS)|Utang marang Ekuitas dyadic.com (DYAI)|Total Utang marang Modal NNVC|Talphera Corporation - Koefisien Total Utang marang Modal|Utang marang Ekuitas Cocrystal Pharma, Inc. (COCP)|Traws Pharma, Inc. (TRAW) - Rasio Kabeh Utang marang Dana Pribadi|DWTX: Rasio Total Utang marang Ekuitas|QLGN (Qualigen Therapeutics Inc) - Total Utang marang Modal|ALVR: Utang marang Ekuitas|Koefisien Total Utang marang Modal VBI Vaccines Inc|Virios Therapeutics - Total Utang marang Modal|Utang marang Modal VXRT (vaxart.com)